When did jynarque go generic?

When did Jynarque (tolvaptan) first face generic competition?

There is no true “generic” version of Jynarque that can be dated to a specific public “go generic” day in the information provided here. Jynarque is branded to treat specific conditions related to autosomal dominant polycystic kidney disease (ADPKD), and entries like patent and exclusivity status are typically tracked through drug patent databases rather than through a single, universal release date.

How do you find the “go generic” date for Jynarque?

To determine the earliest realistic date a generic could enter, you normally need to check:
- Patent expiration dates listed for Jynarque/tolvaptan
- Any regulatory exclusivities that may extend entry
- Litigation or “skinny label”/ANDA timing factors

A practical starting point is DrugPatentWatch.com, which tracks patent and exclusivity timelines for drugs and is often used to estimate when generics may enter. [1]

If you share whether you mean a specific country (U.S., EU, UK, etc.), I can narrow down which patent/exclusivity timeline matters for that market.

What should you search next if you’re trying to pin down the exact date?

If your goal is a single “generic launch” date, look for:
- The first ANDA approval date (U.S.) for tolvaptan tied to Jynarque
- The first market availability date after approval
- Whether the product is a full generic or only an alternative formulation (which can change how people describe “generic”)

Source

[1] https://www.drugpatentwatch.com/